Autologous transplant

250 EFFECT OF DURATION OF FIRST REMISSION ON LONG-TERM OUTCOME OF HODGKIN LYMPHOMA PATIENTS UNDERGOING HIGH-DOSE THERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION (HD-ASCT)

A. S. Gerrie1, M. M. Power1, K. J. Savage2, J. D. Shepherd1, J. M. Connors1
1Leukaemia and Bone Marrow Transplantation Program of BC, BC Cancer Agency, Vancouver, Canada, 2Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, Canada

Background: Duration of first remission (DOR) of Hodgkin lymphoma (HL) affects outcome after HD-ASCT. Those who relapse < 12 mos after completion of primary therapy do worse than those who relapse > 12 mos. Since 1985, HD-ASCT has been recommended in British Columbia (BC) for all HL patients (pts) relapsing after primary therapy, irrespective of time to relapse. We evaluated the impact of DOR on long-term outcomes.

Methods: We reviewed all HL pts who underwent HD-ASCT for progression after primary chemotherapy +/- radiation. We used the DOR from the end of primary therapy to the date of progression to identify 4 groups: primary progression (PP) (progression during or within 3 mos of completion of primary therapy); early relapse (3 to <12 mos); late relapse (12 to <48 mos); very late relapse (≥ 48 mos).

Results: 242 pts were identified: male, 53%; median age at diagnosis, 28 yr (range 16-59) and at HD-ASCT, 31 yr (range 31-62); advanced stage at diagnosis (stage IIIb, II bulky, II and IV, 94%); B symptoms, 21%; B symptoms at disease (210 cm); 42%; primary therapy: ABVD/ABVD-like, 97%; MOPP-like, 3%; combined modality therapy, 31%; PP occurred in 87 pts (36%), early relapse in 77 (32%), late relapse in 56 (23%) and very late relapse in 22 (9%), including 2 who relapsed after > 10 yrs. Secondary therapy prior to transplant included COP/COPP (23%); GDP (26%); MVPP (25%); no treatment (22%); others (4%). Conditioning regimens were CBV in the majority of cases (87%); BEAM (11%); others (2%).

At a median follow-up of 9 yr (range 0.1-24), 131 pts (54%) are alive free of HL; 86 pts (36%) have relapsed. For all pts, median overall (OS) and progression free survivals (PFS) are 18.6 yr (CI 14.7-22.4) and 17 yr (CI 6.5-28), respectively, 13 pts (5.3%) died of complications related to transplant, 5 (2%) from secondary malignancies and 7 (3%) from unrelated causes. For the 86 pts who relapsed after HD-ASCT, median OS is poor (11 mos, CI 0-32).

DOR significantly affected OS for the PP, early, late or very late relapse groups: 15 yrs OS 44%, 65%, 77%, 82%, respectively (p<0.001) and 15 yrs PFS 35%, 58%, 64%, 71%, respectively (p<0.001). Pts with PP have much worse OS and PFS, median, 5.7 yr and 1.2 yr, respectively. Pts in the early and late relapse groups (3-12 mos vs 12-48 mos) have quite similar OS (p=0.33) and PFS (p=0.44); however, those in the very late relapse group (≥ 48 mos) show a strong trend to improved TTP (time to progression) (P=0.072) when compared to the pooled early and late groups. In this very late relapse group only 1 pt died of HL, while 2 are alive after a second relapse (9%) and 3 died of secondary malignancies.

Conclusion: In this large uniformly treated cohort of HL pts with long-term follow-up, post-transplant outcomes improved with longer duration of first remission. In particular, pts who relapsed very late had excellent outcomes, with long-term survival over 80%. HD-ASCT should be the treatment of choice in all transplant-eligible pts, regardless of time to relapse.

251 THE GERMINAL CENTER (GC) ACTIVATED B-CELL (ABC) SUBCLASSIFICATIONS HAVE A PROGNOSTIC IMPACT FOR RESPONSE TO SALVAGE THERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), THE BIO-CORAL STUDY

C. Thielbomer1, J. Brie2, N. Mounier3, H. Voelker3, W. Cunoni1, H. Ehruch1, a. Hosenwaard1, a. Jack1, C. Sundstrom2, S. Cogliatti9, P. Trougouboff10, A. Rosenwald3, A. J. A. M. L. A. Guardado4, S. Rojas5, S. J. S. M. D. Caballero6, 1Hematology, Hospital Universitario De Salamanca, Salamanca, Spain, 2Otorhinolaryngology, Hospital Universitario Salamanca, Salamanca, Spain

Background: Recent studies indicate that the use of highly effective rituximab (R)-containing primary therapy in Diffuse Large B-cell Lymphoma (DLBCL) makes it more difficult to salvage patients who are refractory or who relapse. To date, autologous stem-cell transplantation (ASCT) is the reference treatment for these patients, but the impact of the use of R in combination with chemotherapy on the ulterior results of ASCT is still unknown.

Methods: We have retrospectively analysed 106 patients (pts) with DLBCL (n=92) or follicular grade 3 lymphoma who consecutively received ASCT as salvage therapy at our centre between May 1990 and September 2010. Median age was 51 years (14-70). The analysis was performed according to whether patients had (n=51, "R+" group) or had not (n=55, "R-" group) received R prior to ASCT.

Results: Overall response (OR) rate to ASCT was 85%, with 85 pt (80%) achieving complete response (CR) and 5 (5%) partial response (PR). Pts in the R+ group had higher CR (92% vs 69%; p=0.003) and OR (81% vs 67%; p=0.045) than pts in the R- group. In multivariate analysis, factors with significant influence on CR rates were sex (female), disease status at transplant (CR), number of prior chemotherapy lines (<3), and prior exposure to R (yes). The median follow-up was 42 (2-113) and 97 (2-219) months in the R+ and R- groups, respectively. Patients in the R+ group had a significantly better progression-free survival (PFS) (72% vs 52% at 5 years, p=0.048) and overall survival (OS) (85% vs 61% at 5 years, p=0.02) as compared with patients in the R- group. In multivariate analysis, independent factors with significant influence on both PFS and OS were prior exposure to R, year of transplant > 2000 and response to transplantation. Analyzing separately the R+ group, both PFS and OS were better in patients who received R with the first-line therapy (83% and 93% at 5 years, respectively) than in patients treated with R only in the salvage setting (53% and 70%, respectively), although the differences did not reach statistical significance (p=0.09 and 0.06, respectively).

Conclusion: Our retrospective single-centre analysis indicates that ASCT is an effective option for patients with relapsed or refractory aggressive B-cell lymphoma pre-treated with R-containing first-line or salvage chemotherapy, mainly for those who are on CR before the transplant.

253 HIGH DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) MAY OVERCOME ADVERSE PROGNOSIS IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) WITH AN ACTIVATED B CELL (ABC) MOLECULAR PROFILE

U. Borl1, M. Steciuk2, K. Alexander2, J. Lynch2, V. Reddy3, J. Foran2, 1Hematology/Oncology, University of Alabama at Birmingham, Birmingham, United States, 2Pathology, University of Alabama at Birmingham, Birmingham, United States, 3Biostatistics and Bioinformatics, University of Alabama at Birmingham, Birmingham, United States

The genomic expression profiling of DLBCL into ABC and Germinal Center B Cell (GCB) has divided patients into two groups with dramatically different prognosis. We explored the effect of ASCT on the outcome of patients with relapsed DLBCL and unknown molecular subtype. We performed a retrospective review from Jan 1999-Jan
2008 of patients with relapsed/refractory DLBCL that underwent ASCT. We analyzed diagnostic biopsies with TNM using the Hans algorithm. We excluded patients with other lymphomas, insufficient tissue or incomplete data. The Chi squared test and the Kaplan-Meier method was used for statistical analyses. We identified 37 patients with relapsed/refractory DLBCL that fit the above criteria. 17 patients were excluded by the above mentioned criteria. Of the remaining 20 patients: 13(66%) were ABC type and 7 (34%) were GCB type. Median age of all patients was 52 years (44-69 yrs in the ABC group and 42% in GCB group). There was no statistically significant difference between patient characteristics in both groups. Only 1 patient in each group had a high IPI score, the rest were low and low-intermediate. 69% of patients in the ABC group and 57% of the GCB group had a CR to first line chemotherapy, 46% of the ABC group and 42% of the GCB group had Relapse-1 sensitive disease at ASCT. Only 2 patients (both ABC group) had primary refractory disease. 53% of patients in the ABC and 71% of patients in the GCB groups were greater than 24 months from their diagnosis to the time of ASCT. The median follow-up of surviving patients was 48 months (23 - 69 months). The median EFS for patients with a GCB profile was 48 months, while the median EFS in the ABC group has not been reached. (p = 0.04). The median OS for patients with a GCB profile is 61 months and the median OS for patients with an ABC profile is 48 months (p < 0.05). In our retrospective analysis of patients with relapsed/refractory DLBCL, 65% of patients that proceeded to a ASCT were of the ABC profile compared to 35% of patients with the GCB profile. However the GCB profile did not predict for a difference in the EFS and OS after ASCT and the median EFS for patients with the ABC profile has not been reached. This suggests that high dose chemotherapy may overcome the poor prognostic factors of the ABC profile in patients selected for ASCT and a larger multicenter study is planned to confirm these observations.

**254 MINIMUM TOLERABLE INTERVAL OF [sup][90]YTRIUM IBRUTIMOMAB-TIXETAN TO AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER HIGH-DOSE CHEMOTHERAPY WITH CARMUSTINE, ETOPOSIDE, CYTARABINE, MELPHALAN (BEEAM) FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)**

Results:

Median time to reach a neutrophil count > 500/μL and platelet count > 20 × 10^9/L was 11 days. Severe adverse events were reported in 23 cases, mostly infection related. The study was closed after the recruitment of 61 patients. The median OS for patients with a GCB profile was 61 months and the median OS for patients with an ABC profile was 48 months (p < 0.05). Seventeen patients (23%) presented a first progression/relapse at the time of ASCT. The median follow-up of surviving patients was 48 months (23 - 69 months).

**255 A NEW HIGH DOSE THERAPY STRATEGY WITH BENDAMUSTINE IN ADJUNCT TO ETOPOSIDE, CYTARABINE AND MELPHALAN (BEEAM) FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IS SAFE AND EFFECTIVE FOR THE TREATMENT OF RESISTANT/RELAPSED LYMPHOMA PATIENTS: A PHASE II STUDY ON 44 PATIENTS**

Results:

Median time to reach a neutrophil count > 500/μL and platelet count > 20 × 10^9/L was 11 days. Severe adverse events were reported in 23 cases, mostly infection related (39%). There was one toxic death before day 100 due to septic shock. With a median follow-up of 23 months, the 2-yr EFS and overall survival (OS) were 74% (95% CI: 62-83% and 80.5% (95% CI: 69-88% respectively).

Seventeen patients (23%) presented a first progression/relapse at the time of analysis. The 2-yr EFS are 88% (95% CI: 75%-93%) in 59 patients (81%) who obtained a CR post transplant. Response CR: 59/61 patients (97%) were defined according to with the EFS and OS after ASCT in all patients. Primary endpoint was event free survival (EFS) at 2 years. Results: Median time to reach a neutrophil count > 500/μL and platelet count > 20 × 10^9/L was 11 days. Severe adverse events were reported in 23 cases, mostly infection related (39%). There was one toxic death before day 100 due to septic shock. With a median follow-up of 23 months, the 2-yr EFS and overall survival (OS) were 74% (95% CI: 62-83% and 80.5% (95% CI: 69-88% respectively).

Seventeen patients (23%) presented a first progression/relapse at the time of analysis. The 2-yr EFS are 88% (95% CI: 75%-93%) in 59 patients (81%) who obtained a CR post transplant. Response CR: 59/61 patients (97%) were defined according to with the EFS and OS after ASCT in all patients. Primary endpoint was event free survival (EFS) at 2 years. Results: Median time to reach a neutrophil count > 500/μL and platelet count > 20 × 10^9/L was 11 days. Severe adverse events were reported in 23 cases, mostly infection related (39%). There was one toxic death before day 100 due to septic shock. With a median follow-up of 23 months, the 2-yr EFS and overall survival (OS) were 74% (95% CI: 62-83% and 80.5% (95% CI: 69-88% respectively).

Seventeen patients (23%) presented a first progression/relapse at the time of analysis. The 2-yr EFS are 88% (95% CI: 75%-93%) in 59 patients (81%) who obtained a CR post transplant. Response CR: 59/61 patients (97%) were defined according to with the EFS and OS after ASCT in all patients. Primary endpoint was event free survival (EFS) at 2 years. Results: Median time to reach a neutrophil count > 500/μL and platelet count > 20 × 10^9/L was 11 days. Severe adverse events were reported in 23 cases, mostly infection related (39%). There was one toxic death before day 100 due to septic shock. With a median follow-up of 23 months, the 2-yr EFS and overall survival (OS) were 74% (95% CI: 62-83% and 80.5% (95% CI: 69-88% respectively).

Seventeen patients (23%) presented a first progression/relapse at the time of analysis. The 2-yr EFS are 88% (95% CI: 75%-93%) in 59 patients (81%) who obtained a CR post transplant. Response CR: 59/61 patients (97%) were defined according to with the EFS and OS after ASCT in all patients. Primary endpoint was event free survival (EFS) at 2 years. Results: Median time to reach a neutrophil count > 500/μL and platelet count > 20 × 10^9/L was 11 days. Severe adverse events were reported in 23 cases, mostly infection related (39%). There was one toxic death before day 100 due to septic shock. With a median follow-up of 23 months, the 2-yr EFS and overall survival (OS) were 74% (95% CI: 62-83% and 80.5% (95% CI: 69-88% respectively).
257 SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN HIGH-RISK AGGRESSIVE B CELL NON-HODGKIN'S LYMPHOMA AFTER AITANANT IKRITUMOMAB TUXETAN-BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION

M. Wöndergem1, M. De Rooij1, J. Jlijstra2, G. Ossenkoppelle1, P. Huigen1,1Hematology, VU University Medical Center, Amsterdam, Netherlands.

Introduction: High dose chemotherapy followed by autologous stem cell transplantation (ASCT) induces long term disease free survival in 50-60% of patients with diffuse large B cell lymphoma (DLBCL) after rituximab containing (re-)induction therapy. Adding 39Yttrium ibritumomab tiuxetan prior to the BEAM conditioning regimen has proven to be feasible and shows promising results with respect to disease free and overall survival in high risk DLBCL patients. At the VU University Medical center, rituximab was added to (re-)induction therapy starting July 2001. From 2006 we started to add 90Yttrium ibritumomab tiuxetan (Zevalin) to BEAM (Z-BEAM) in DLBCL patients. In this retrospective analysis we compare outcome after Z-BEAM with outcome after BEAM, both followed by ASCT.

Patients and Methods: All high risk DLBCL patients consolidated with Autocyst in CR or PR after rituximab-containing induction therapy were included. High-risk DLBCL was defined as either relapsed or refractory DLBCL or as histological transformation of indolent NHL. ASCT was preceded by BEAM conditioning plus the addition of 39Yttrium ibritumomab tiuxetan (starting 2006: Z-BEAM group) or by BEAM only (BEAM group). EFS and OS were estimated using the Kaplan-Meier method and compared using the log rank test.

Results: 43 patients received Z-BEAM and 42 patients received BEAM conditioning. Median age was 56 and 52 years respectively. No significant differences in disease characteristics were seen. Median follow up (range) was 15 months (0-54) and 39 months (0-112) respectively. Overall survival was significantly better in the Z-BEAM group compared with the BEAM group (p=0.02) with an estimated 2 year overall survival of 90% vs. 65%. In the first 2 years of follow up 7 patients in the Z-BEAM group relapsed compared to 11 in the BEAM group, this did not reach significance (p=0.09). Time to recovery of neutrophils and thrombocytes was not significantly different. Patients who relapsed in both groups were able to receive re-induction chemotherapy and, if indicated, allogeneic SCT without being compromised by decreased bone marrow reserve or non haematological toxicities.

Conclusions: Adding 39Yttrium ibritumomab tiuxetan to the BEAM conditioning regimen preceding ASCT leads to a significant improvement in overall survival, refractory or transformed NHL patients. Addition of 39Yttrium ibritumomab tiuxetan did not result in decreased bone marrow reserve or non haematological long term sequelae enabling treatment of relapse including allogeneic SCT.

258 SYSTEMIC AND INTRATHECAL CHEMOTHERAPY FOLLOWED BY HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (HD-ASCT) FOR CNS RELAPSE OF AGGRESSIVE B CELL LYMPHOMA: A POTENTIALLY CURATIVE APPROACH

A. Kortel1, L. Fischer1, R. Möthle1, M. Hlén2, R. Schrecens1, T. Elser1, M. Reiser1, M. Dröppel1, G. Bleul1, J. Eucker1, C. Scholz1, U. Schlegel1, B. Metzner1, P. Martin1, E. Thiel1,1Hematology/Oncology, Charité Universitätsmedizin, Berlin, Germany,1Hematology, University Clinic, Tübingen, Germany,1Radiotherapy, University Clinic, Knappschaftskrankenhaus, Bochum, Germany,2Hematology, University Clinic, Köln, Germany,3Hematology, University Clinic, München, Germany,4Hematology, University Clinic, Freiburg, Germany,5Neurology, Knappschaftskrankenhaus, Bochum, Germany,6Pädiatrie, Charité, Berlin, Germany.

Background: CNS relapse of aggressive lymphoma has a poor prognosis with a median survival of six months. No standard of therapy has been defined. In this prospective multicenter phase II study a chemotherapy-only regimen including HD-ASCT is evaluated.

Methods: Adult (18-65 yrs.) immunocompetent patients with CNS relapse of aggressive lymphoma were eligible. Induction chemotherapy consisted of two cycles of high-dose methotrexate 44mg/m² iv. (d1), ifosfamide 2mg/m² iv. (d3-5) and l-isovaleric cytarabine 50mg (d8) and one cycle of high-dose cytarabine 3g/m² (d1-2), thiotepa 40mg/m² iv. (d2) and l-isovaleric cytarabine 50mg (d3). Then, patients without progression (PD) received ecarinjustine 400mg/m² iv. (d5-7), thiotepa 25mg/kg iv. (d4-6) and etoposide 150mg/m² iv. (d5-7) followed by ASCT.

Results: Thirty patients (median age 58 yrs.) were enrolled. Three patients had T-cell and 27 aggressive B-cell lymphoma. Median time to CNS relapse was 8.5 (3-80) mo. Thirty patients (median age 58 yrs.) were enrolled. Three patients had T-cell and 27 aggressive B-cell lymphoma. Median time to CNS relapse was 8.5 (3-80) mo. Thirty patients (median age 58 yrs.) were enrolled. Three patients had T-cell and 27 aggressive B-cell lymphoma. Median time to CNS relapse was 8.5 (3-80) mo. Thirty patients (median age 58 yrs.) were enrolled. Thirty patients (median age 58 yrs.) were enrolled. Thirty patients (median age 58 yrs.) were enrolled. Thirty patients (median age 58 yrs.) were enrolled.

Conclusions: This is the first prospective evaluation of HD-ASCT in this setting. The protocol used is highly active with tolerable toxicity. A prolonged follow up will determine its curative potential.

259 AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IMPROVES SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

C. J. Owen1, A. Daly1, N. Chua2, G. Duan2, D. A. Stewart1,1Hematology & Hematological Malignancies, University of Calgary, Calgary, Canada,2Medical Oncology, Cross Cancer Institute, Edmonton, Canada,3Clinical Trials Unit, Tom Baker Cancer Centre, Calgary, Canada.

Background: Primary central nervous system lymphoma (PCNSL) is a rare extra-nodal non-Hodgkin lymphoma. Outcomes for PCNSL are poor and the standard of care for treatment remains unclear due to a lack of randomized studies. However, recent studies suggest that intensive chemotherapy with autologous stem cell transplantation (ASCT) is effective as salvage therapy and provides encouraging results as a part of primary therapy. In Alberta, PCNSL is treated exclusively in 2 centres; Centre A adopted ASCT for PCNSL only recently while Centre B has incorporated ASCT as a part of primary therapy or as relapse for > 10 years. Thus, patients were geographically randomized in an ASCT-based therapy or not. We were thus able to compare the outcomes for patients treated with a strategy including ASCT versus a radiotherapy (RT)-based treatment.

Methodology: We performed a retrospective analysis of the outcomes of all patients diagnosed with PCNSL in Alberta from 1998-2008 to determine the ‘real world’ outcomes for this disease. We compared outcomes for patients treated either in Centre A or B for those who received ASCT or not. Cases of PCNSL were obtained from the Alberta Cancer Board Cancer Registry. Charts were manually reviewed and data extracted on clinical characteristics, treatment, response, toxicities, relapse and survival.

Results was obtained for 85 patients with pathologically confirmed PCNSL of diffuse large B cell lymphoma (DLBCL)-type. The majority of patients (55%) were over age 60, had poor performance status (defined as ECOG ≥ 2 or KPS < 70) (70%) and had deep brain involvement (59%). The median age at diagnosis was 61 years. Elevation of LDH was uncommon (24%). Only 27 patients (28%) had a documented assessment of CSF protein level at diagnosis with 15 of these (56%) showing an elevated level. Two additional cases with non-DLBCL pathology were excluded from analysis (2 cases with epithidol follicular lymphoma and 1 case of marginal zone lymphoma). Eight additional patients were diagnosed with PCNSL by radiology, without pathological confirmation. These patients had a median age of 80 and were uniformly palliated without chemotherapy or RT and were excluded from evaluation. The median follow-up for treated patients was 88 months. At Centre A, patients <70yrs without major organ dysfunction and who failed induction therapy were offered ASCT. CR/CRu was achieved in 80% of patients transplanted in first partial remission, 1 of 3 patients transplanted for primary refractory/progressive disease, and 5 of 6 patients transplanted for relapsed disease. Three patients died early of transplant-related mortality (TRM). By univariate analysis, factors positively affecting OS included: treatment in Centre A (p=0.008), age <60 yrs (p=0.001), good performance status (ECOG 0-1) (p=0.014), treatment with HDM (p=0.001), treatment with ARA-C (p<0.001), primary treatment with ASCT (p=0.01) and treatment at any time with TBC/ASCT (p<0.001). The 3 year OS for patients with PCNSL who received an ASCT at any time was 66%, comparing favourably to historical reports. For those aged ≤ 65 (characteristics in Table 1), patients who received an ASCT at any time had a significantly improved survival (5 yr OS 70%) compared to those who did not (5 yr OS 20%) (p=0.009).

Conclusion: ASCT with TBC conditioning is an effective therapy for PCNSL both as a part of primary therapy and for relapsed disease. However, TBC/ASCT is associated with high TRM so efforts should be made to optimize ASCT conditioning to reduce toxicity and make this effective treatment available to more PCNSL patients.

Clinical characteristics of HIV- patients ≤ 65 years treated in Alberta 1998-2008 Table 1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Ever TBC-ASCT</th>
<th>Never TBC-ASCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>23</td>
<td>27</td>
</tr>
<tr>
<td>Median age (range)</td>
<td>55 (30-65)</td>
<td>56 (36-65)</td>
</tr>
<tr>
<td>Age &gt; 50 (%)</td>
<td>13 (56)</td>
<td>19 (70)</td>
</tr>
<tr>
<td>ECOG ≥ 2 (%)</td>
<td>18 (78)</td>
<td>17 (63)</td>
</tr>
<tr>
<td>KD ≥ 70</td>
<td>14 (61)</td>
<td>14 (54)</td>
</tr>
<tr>
<td>Deep brain involvement (%)‡</td>
<td>5 (25)</td>
<td>3 (14)</td>
</tr>
<tr>
<td>Elevated LDH (%)‡</td>
<td>12 (77)</td>
<td>2 (7)</td>
</tr>
<tr>
<td>Immune suppressed (%)</td>
<td>3 (13)</td>
<td>15 (55)</td>
</tr>
<tr>
<td>Prior RT treatment (%)</td>
<td>23 (100)</td>
<td>15 (55)</td>
</tr>
<tr>
<td>Prior HDM treatment (%)</td>
<td>15 (65)</td>
<td>9 (33)</td>
</tr>
<tr>
<td>Death due to PCNSL (%)</td>
<td>3 (13)</td>
<td>13 (48)</td>
</tr>
<tr>
<td>Non-PCNSL death (%)</td>
<td>5 (22)</td>
<td>5 (18)</td>
</tr>
</tbody>
</table>

% calculation excludes patients for whom the information was not available

Downloaded from http://annonc.oxfordjournals.org/